This Cancer Drug Candidate Could Be a Hit for Pfizer

The FDA recently accepted the drugmaker's regulatory filing for review of a potential drug to treat a type of blood cancer.

Related Keywords

Bristol Myers Squibb Revlimid ,Johnson Darzalex ,Drug Administration ,Imarc Group ,Pfizer ,Bristol Myers Squibb ,